1.60

4.19% -0.07

Celularity Inc (CELU)

Overview News Price History Option Chain Financials Discussions Forecast

Celularity Inc stock is traded at $1.60, with a volume of 95,316. It is down -4.19% in the last 24 hours and down -4.76% over the past month. Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Previous Close:

$1.67

Open:

$1.7

24h Volume:

95,316

Relative Volume:

0.78

Market Cap:

$45.33M

Revenue:

$48.20M

Net Income/Loss:

$-35.05M

P/E Ratio:

-1.0209

EPS:

-1.5673

Net Cash Flow:

$-13.02M

1W Performance:

-19.19%

1M Performance:

-4.76%

6M Performance:

-9.09%

1Y Performance:

-30.43%

1-Day Range:

$1.58

$1.725

1-Week Range:

$1.58

$1.98

52-Week Range:

$1.06

$4.35

Celularity Inc Stock (CELU) Company Profile

Name

Celularity Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

(908) 768-2170

Address

170 PARK AVE, FLORHAM PARK

Employee

123

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

CELU's Discussions on Twitter

Compare CELU with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CELU Celularity Inc	1.60	47.31M	48.20M	-35.05M	-13.02M	-1.5673
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Celularity Inc Stock (CELU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jun-22-22	Initiated	H.C. Wainwright	Buy
Apr-06-22	Downgrade	Truist	Buy → Hold
Jan-28-22	Initiated	Oppenheimer	Outperform
Nov-24-21	Initiated	Morgan Stanley	Equal-Weight

View All

Celularity Inc Stock (CELU) Latest News

Dec 12, 2025

Market Outlook: Why Celularity Inc Equity Warrant stock is considered a top pickWeekly Trade Summary & Weekly Chart Analysis and Guides - moha.gov.vn

Dec 12, 2025

Dec 08, 2025

Celularity receives FDA warning over marketing claims - MSN

Dec 08, 2025

Dec 06, 2025

Celularity Shares Face Persistent Headwinds Amid Regulatory and Financial Challenges - AD HOC NEWS

Dec 06, 2025

Dec 05, 2025

Celularity Receives FDA Warning Over Marketing Claims - TipRanks

Dec 05, 2025

Celularity Inc Receives FDA Warning Letter - TradingView — Track All Markets

Dec 05, 2025

Is Celularity Inc. Equity Warrant stock attractive for ETFsTrade Volume Report & Growth Oriented Trade Recommendations - Newser

Dec 05, 2025

Dec 04, 2025

Will Celularity Inc. Equity Warrant stock benefit from commodity pricesWeekly Gains Summary & Growth Focused Stock Reports - Newser

Dec 04, 2025

Is Celularity Inc. Equity Warrant stock positioned for digital transformationMarket Performance Summary & Technical Confirmation Trade Alerts - Newser

Dec 04, 2025

Dec 03, 2025

Why analysts upgrade Celularity Inc. stockForecast Cut & Free Technical Pattern Based Buy Signals - Newser

Dec 03, 2025

Is Celularity Inc. Equity Warrant stock a safe investment in uncertain markets - Newser

Dec 03, 2025

Dec 02, 2025

Celularity (CELU) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 02, 2025

Nov 29, 2025